Surviving a single infection often results in lifelong immunity to the infecting pathogen. Such
protection is mediated, in large part, by two main B cell memory 'walls'—namely, long-lived …

Executive summary 50 years after a noble but flawed attempt to eradicate malaria in the mid-
20th century, the global malaria community is once again seriously considering eradication …

Background Additional interventions are needed to reduce the morbidity and mortality
caused by malaria. Methods We conducted a two-part, phase 1 clinical trial to assess the …

Immunity to malaria has been linked to the availability and function of helper CD4+ T cells,
cytotoxic CD8+ T cells and γδ T cells that can respond to both the asymptomatic liver stage …

Discovering potent human monoclonal antibodies (mAbs) targeting the Plasmodium
falciparum circumsporozoite protein (PfCSP) on sporozoites (SPZ) and elucidating their …

Vaccine development has the potential to be accelerated by coupling tools such as systems
immunology analyses and controlled human infection models to define the protective …

Malaria remains a significant contributor to the global burden of disease, with around 40% of
the world's population at risk of Plasmodium infections. The development of an effective …

Over 75% of malaria-attributable deaths occur in children under the age of 5 years.
However, the first malaria vaccine recommended by the World Health Organization (WHO) …

Background Malaria in pregnancy has major impacts on mother and child health. To
complement existing interventions, such as intermittent preventive treatment and use of …

The generation of high-quality antibody responses to Plasmodium falciparum (Pf)
circumsporozoite protein (PfCSP), the primary surface antigen of Pf sporozoites, is …